1. Overview of Cancer Patients in United States in 2023
2. How Spade Health Work
Every year, the American Cancer Society estimates the number of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes from central cancer registries and the National Centre for Health Statistics. In 2023, the United States is expected to have 1,958,310 new cancer cases and 609,820 cancer deaths.
After two decades of reduction, prostate cancer incidence increased by 3% each year from 2014 to 2019, resulting in an additional 99,000 new cases; otherwise, incidence trends were more favourable in men than in women. From 2015 to 2019, for example, lung cancer in women reduced at half the rate of males (1.1% vs. 2.6% annually), whereas breast and uterine corpus cancers increased, as did liver cancer and melanoma, all of which stabilised in men aged 50 and older and declined in younger men.
However, a 65% decrease in cervical cancer incidence among women in their early twenties, the first cohort to receive the human papillomavirus vaccine, from 2012 to 2019, portends substantial reductions in the burden of human papillomavirus-associated cancers, the majority of which occur in women.
Despite the pandemic, and in contrast to other main causes of mortality, the cancer death rate decreased (by 1.5%) from 2019 to 2020, adding to a 33% overall drop since 1991 and an estimated 3.8 million deaths avoided. This success increasingly reflects advances in therapy, as evidenced by rapid declines in mortality (roughly 2% per year from 2016 to 2020) for leukaemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated falls for lung cancer.
The projected number of new invasive cancer cases in the United States in 2023, broken down by gender and disease type. There will be around 1,958,310 new cancer cases, the equivalent of approximately 5370 cases every day. Furthermore, there will be approximately 55,720 new instances of ductal carcinoma in situ in women and 89,070 new cases of cutaneous melanoma in site.
In conclusion, while cancer death rates continue to fall, future progress may be hampered by the increasing incidence of breast, prostate, and uterine corpus cancers, which likewise have the highest racial differences in mortality.
The figure above depicts the most prevalent malignancies diagnosed in men and women in 2023. Prostate, lung, and bronchus cancers, as well as colorectal cancers (CRCs), account for about half of all incident cases in men, with prostate cancer accounting for 29% of diagnoses. Breast cancer, lung cancer, and colorectal cancer account for 52% of all new diagnoses in women, with breast cancer alone accounting for 31% of female cancers.
Spade Health is a leading Healthcare Market Research Firms. We have the best market researchers, business analysts, and business consultants on our team. For our clients, we create time-bound strategic roadmaps.
Spade Health specializes in market research and studies for Clinical Laboratory Equipment, Pathology Equipment, Surgical Products, Medical Equipment, Hospital Equipment and Furniture, Radiology and Microbiology Equipment, and so on.
We have conducted hundreds of studies in the healthcare sector analyzing trends in molecule usage, specialists’ perceptions of the rise in molecule usage for diseases, prescription practises of specific molecules, surgical products such as catheters, blood bags, sutures, syringes, cardiac equipment, and wood care therapy.
In-depth interviews with general practitioners, specialists, medical administrators, hospital administrators, distributors, and retailers are part of this study. We had the pleasure of working with successful Indian organizations in the Pharmaceuticals and Healthcare sectors market research. Because these are all customized research analyses, the approach changes with every assignment.
Since 1991, the cancer mortality rate has steadily declined, resulting in a 33% overall decrease and an estimated 3.8 million cancer deaths avoided. This consistent progress is due to smoking cessation, increased screening for breast, colorectal, and prostate cancers, and advances in treatment, such as adjuvant chemotherapies for colon and breast cancers.
More recently, advances in the development of targeted treatment and immunotherapy have accelerated progress in lung cancer mortality far beyond incidence reductions, as evidenced by large mortality reductions for cancers with increasing or stable incidence (leukaemia, melanoma, and kidney cancer). Treatment advances have greatly improved the treatment of some difficult-to-treat malignancies, including nonsmall cell lung cancer and metastatic melanoma.
Rising occurrences of breast, prostate, and uterine corpus cancers, all of which have a wide racial gap in mortality and are amenable to early identification, are cause for concern. Expanding access to care and increasing investment in research to expand treatment choices and develop viable initiatives to minimize inequality will help lessen inequities and accelerate progress against cancer.